• General
  • Industry
  • Government & Politics
  • Other Language
  • Press Release
  • Home
  • Submit News
  • Contact Us
  • About Us
Pakistan Newswire
Menu
  • General
  • Industry
  • Government & Politics
  • Other Language
  • Press Release
 › Press Release › Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

Web Desk September 10, 2021     Comment Closed     Press Release

Independent Data Monitoring Committee Supports Expansion to Adolescents and Pregnant and Nursing Women Based on Safety and Tolerability Data from Phase 2 Lead-In

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women, as well as to decrease the protocol-specified, post injection monitoring time. The IDMC’s assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio remains blinded to the data and plans to implement the IDMC recommendations for the Phase 3 portion of the trial. EVADE is being conducted globally, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, to evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.

“Given the urgent need for additional treatment and preventative options for COVID-19, particularly in vulnerable populations, we are pleased that an independent assessment of the safety data from the lead-in portion of EVADE supported inclusion of adolescents and pregnant or nursing women in the next phase of the study,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options.”

The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit https://clinicaltrials.gov/ct2/show/NCT04859517.

The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com


Press Release
AfricaMENAPakistanSouth Africa

 Previous Post

FDE to organize e-Kachehri on Monday

― September 10, 2021

Next Post 

Rain with wind, thundershower expected in Punjab, Sindh, KP, Balochistan, GB & Kashmir

― September 11, 2021

Related Articles

Web Desk ― January 26, 2023 | Comment Closed

EB5 Capital Celebrates Ribbon-Cutting for Rivergate (JF28)

WASHINGTON, Jan. 25, 2023 (GLOBE NEWSWIRE) — Today, members of the EB5 Capital team joined developer IDI Group Companies and PTM Partners in celebrating the ribbon-cutting ceremony of Rivergate, also known as Viridium, EB5 Capital’s JF28 project located in Woodbridge, Virginia. This event marks a major milestone for the project, which is the second phase […]

Web Desk ― January 26, 2023 | Comment Closed

‫اعتماد اور شفافیت کو فروغ دینے کے لئے اِن ڈرائیو پارٹنرز شیلڈ میں گلوبل رائیڈ ہیلنگ پلیٹ فارم

Web Desk ― January 26, 2023 | Comment Closed

Global Ride-Hailing Platform inDrive Partners SHIELD to Boost Trust and Fairness

Web Desk ― January 25, 2023 | Comment Closed

اثراء نے درعیہ اسلامک آرٹس بینالی میں سلطنت سعودی عربیہ کے ثقافتی ورثے کے بارے میں جاننے اور سیکھنے کے نئے طریقے پیش کیے

Web Desk ― January 25, 2023 | Comment Closed

Ithra presents new ways to experience and learn about KSA’s cultural heritage at the Diriyah Islamic Arts Biennale

Web Desk ― January 25, 2023 | Comment Closed

Nikkiso Clean Energy & Industrial Gases Group Announces New Sales and Service Facility in Qatar

Web Desk ― January 24, 2023 | Comment Closed

Duck Creek Technologies recognized for outstanding commitment to Diversity, Equity and Inclusion by Insurance Business America

Web Desk ― January 24, 2023 | Comment Closed

Rosario Ochoa Named General Manager of Nikkiso ACD for Nikkiso Clean Energy and Industrial Gases Group

Search

Follow Us

Recent Posts

  • Pakistan reiterates to raise voice on continuing grave HR abuses in IIOJK January 26, 2023
  • PML-Q terms Pervaiz Elahi’s move to reelect party’s leadership as unconstitutional January 26, 2023
  • British Parliamentarians assure support for Kashmiris’ right to self-determination January 26, 2023
  • Pakistan urges world to take action to protect people of occupied Palestine, IIOJK January 25, 2023
  • Pakistan strongly condemns despicable act of Holy Quran’s desecration in Netherlands January 25, 2023
  • PM felicitates his newly elected counterpart of New Zealand January 25, 2023
  • Pakistan, Qatar to explore areas of cooperation in energy sector January 24, 2023
  • Energy Minister vows to overhaul power transmission system January 24, 2023
  • FM discusses regional, int’l issues with global leaders January 24, 2023
  • Major power breakdown in different parts of Pakistan January 23, 2023
  • President condemns abhorrent act of desecration of Holy Quran in Sweden January 23, 2023
  • Imran put country at stake for sake of personal political ambitions: Naveed Qamar January 23, 2023

Advertisement

Calendar

January 2023
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Dec    


The strategy of the team behind “Pakistan news Wire.Net” is clear and it is to publish only authentic news as that is what the true journalism demands from any media outlet, and the “Pakistan News Wire. Net”, discourages the practice of opting for illegal approaches in order to get the ratings by any means. The more media outlets opt [...]

Archives

Search

Pages

  • Home
  • Submit News
  • Contact Us
  • About Us

Social Links

Copyright © 2020 - Pakistan News Wire. All Rights Reserved.